Cambridge, UK, 9 August 2017 - Microbiotica, a leading player in microbiome-based therapeutics, is delighted to be announced that it has been selected as a finalist in the ‘Best Start-up Biotech Company’ category of the OBN Awards 2017.
Being selected for the shortlist recognises Microbiotica’s commercial potential in the fast growing microbiome space, reflecting its innovative understanding of the gut microbiome and the therapeutic potential to address a host of disorders through microbial targets.
In 2016, Microbiotica was created with £8m funding from Cambridge Innovation Capital and IP Group to commercialise the groundbreaking research of the Wellcome Trust Sanger Institute.
The finalist will be selected on the following criteria: formed for less than two years, has raised substantial financial support (£1m-£20m), is developing novel and disruptive products and has proof of financing raised and ongoing deals in the pipeline, with evidence of a commercialisation strategy.
The winners for all eight categories will be announced at the awards evening on Tuesday 5 October 2017 at the OBN Annual Awards Ceremony at Oxford Town Hall.